The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers

Bradbury, Robyn, Jiang, Wen Guo ORCID: https://orcid.org/0000-0002-3283-1111 and Cui, Yuxin 2015. The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers. Biomarkers in Medicine 9 (12) , pp. 1353-1370. 10.2217/bmm.15.94

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Prostate-specific membrane antigen (PSMA) overexpression is observed in the neovasculature of solid tumors, but not in the vasculature of normal tissues. Increased PSMA expression is positively associated with tumor stage and grade, although its function in cancer remains unclear. Mouse double minute 2 (MDM2) is a negative regulator of the p53 tumor suppressor and is reported to regulate VEGF expression and angiogenesis. Both proteins have been considered as biomarkers and therapeutic targets for advanced solid tumors. Our work and a recent microarray-based gene profiling study suggest there could be signaling interplay between MDM2 and PSMA. We herein review the mechanisms underlining the outgrowth of tumors associated with PSMA and MDM2, their potential interaction and how this may be applied to anticancer therapeutics.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	interplay, MDM2, PSMA, therapy, tumor
Publisher:	Future Medicine
ISSN:	1752-0363
Date of First Compliant Deposit:	30 March 2016
Last Modified:	04 May 2023 22:10
URI:	https://orca.cardiff.ac.uk/id/eprint/85867

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item